The metronidazole market was valued at USD1,377.3Mn by 2019. Rising prevalence of bacterial and parasitic infection worldwide drive the metronidazole market growth. It is still considered as a first-line therapy in bacterial vaginosis, rosacea, amoebiasis, etc. A constant rise in the generic drug market in the developing region further accentuates metronidazole market growth.

Metronidazole belongs to the nitroimidazole class of antibiotics which is used for the treatment of giardiasis, trichomoniasis, amoebiasis, and other parasitic infections. The exact mechanism of action is not known but an intermediate of metronidazole binds to the DNA and electron transport proteins of the microorganism and blocks the synthesis of nucleic acids. It is available as tablets, capsules, topical gels, intravenous fluids with different dose strengths, etc.

The major segments related to the metronidazole market are:

By Treatment (2017–2027; US$ Mn)

Bacterial Vaginosis

Rosacea

Amoebiasis

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global metronidazole market
• The overall segmentation of the metronidazole market, by treatment, distribution channel, and geography is minutely studied. Bacterial vaginosis and hospital pharmacy are dominating the treatment and distribution channel segments respectively
• Significant increase in bacterial vaginosis in female population worldwide
• Constant rise of rosacea encountered in the Caucasian population throughout the globe further consolidate the metronidazole market growth

Report gist?

• The study of the global metronidazole market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of treatment and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the manufacturing and marketing of metronidazole for the treatment of bacterial vaginosis and rosacea worldwide
• The report will benefit researchers engaged in the clinical trial investigation for the therapeutic efficacy of metronidazole in the treatment of pseudomembranous colitis
  Managers with financial institutions looking to publish recent and forecasted statistics pertaining to metronidazole market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Bacterial vaginosis is reigning the treatment segment for the metronidazole market. According to the latest research citings presented by the World Health Organization (WHO), approximately 30% of the women population aged 14 to 49 years experience with bacterial vaginosis infection. It is associated with risk factors such as sexually transmitted diseases, such as syphilis, gonorrhea, AIDS, chlamydia, herpes simplex, etc. Bacterial vaginosis produces a bad odor which leads to grave embarrassment and low self-esteem in women suffering from the disease. Rosacea is anticipated to be the fastest-growing treatment segment in the near future on account of the constant rise in the reported cases in the people belonging to European and Celtic descent. According to the research citings presented by the European Society for Dermatological Research (ESDR), approximately 400 million people worldwide are suffering from rosacea. Constant exposure to extreme cold and heat triggers the occurrence of rosacea in the central part of the face, additionally, alcohol consumption and cigarette smoking further aggravates the situation.

Hospital pharmacy is dominating the distribution channel segment for the metronidazole market. Precise compounding of metronidazole is essential as it is used as a first-line therapy drug in bacterial and parasitic infection. Hospital pharmacist ensures accurate dispensing of metronidazole drug formulation in accordance with the physicians prescription. Retail pharmacy is gaining huge demand in developing countries in order to cater to the medicinal needs of a huge population base and availability of generic drugs at attractive prices.

North America is holding the largest market share in the geography segment for the metronidazole market. Rising prevalence of bacterial vaginosis in women population aged 14 to 49 primarily drives the metronidazole market growth in the region. As per the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately 21.2 million women population in the United States are suffering from bacterial vaginosis. Additionally constant rise in the reported cases of pelvic inflammatory disease further accentuates the market growth in the region. Europe is currently in second place in the regional segment for the metronidazole market. According to the latest research information brought forward by the European Commission the prevalence rate of rosacea is ranging from 9 to 22%, it is highly prevalent in the Caucasian population and has a high incidence rate in the female population in comparison to males. The Asia Pacific is keen to register excellent market growth during the forecast period on account of the rising prevalence of amoebiasis infection across all age groups and the existence of a well-developed generic drug market in the region.